Evercore ISI Group Upgrades BioCryst Pharmaceuticals to Outperform, Announces $16 Price Target

Evercore ISI Group analyst Liisa Bayko upgrades BioCryst Pharmaceuticals (NASDAQ:BCRX) from In-Line to Outperform and announces $16 price target.

Evercore ISI Group analyst Liisa Bayko upgrades BioCryst Pharmaceuticals (NASDAQ:BCRX) from In-Line to Outperform and announces $16 price target.

Total
0
Shares
Related Posts